Novaremed banner3


Novaremed is a pharmaceutical company that utilizes a highly innovative proprietary library of small molecules to develop safer and more efficacious drugs for chronic and life-threatening diseases.

NRD135S-E1 is a first-in-class tyrosine kinase modulator for the treatment of neuropathic pain associated with diabetes.

Eli Kaplan M.D. - Co-Founder & CEO

Dr. Eli Kaplan. has an M.D. from the Bologna University in Italy. He has extensive experience in clinical practice and pharmaceutical research. He has served in key positions in internal and oncology hospital departments, as medical director of Farmitalia Carlo Erba in Germany, as consultant in the drug development field, and as medical director of BreathID in Israel. In recent years Dr. Kaplan has concentrated in research and development of drugs in the field of pain treatment and oncology.

Liat Hochman M.Sc. – Director of Clinical Operations

With more than 17 years of experience in the clinical industry, Liat Hochman has held key Clinical Research Organization (CRO) positions. She established and headed the Israeli office of Hesperion Israel for 9 years, being responsible for country management, clinical operations, and HR. Upon the merger of Hesperion CH with Averion US, she served as Regional Director at Averion International Israel Ltd. Hochman is well recognized in the Israeli clinical operations arena for successful performance and delivery of high quality project deliverables, on time and within budget.

Moshe Shitrit C.P.A. – CFO

Moshe Shitrit has vast experience in the field of finances and accounting, auditing, investing, recruiting finances, and IPOs. Before joining Novaremed, Shitrit served as CEO at the ATI technological incubator focused on Life Sciences and Cleantech, and as CFO of several private and listed companies (TASE & NASDAQ). In parallel with his position at Novaremed, Shitrit serves as board member in other companies.

Michal Freud-Silverberg Ph.D., Clinical Manager

Michal Freud-Silverberg is an expert clinical operation manager. Michal has vast experience in all aspects of conduct and management of clinical trials (since 1997), as well as SOP writing and training. Michal has extensive QA and regulatory knowledge. Michal is a lecturer in the Biotechnology MSc program at Braude college and an active member in the quality forum of CTrials.

Neta Pessah – PhD, Pre-Clinical Manager

Neta Pessah has experience in drug development, pharmacokinetics, and multiple-step organic synthesis. She has participated in the development of pharmacokinetic-based antiepileptic and anti allodynic drugs as well as in the development of drug delivery systems for cancer therapy.